---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-094349"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:25:15.962032+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# InMed Pharmaceuticals granted Nasdaq exception until Dec 2; plans 1-for-20 reverse stock split

## Summary
- Nasdaq Panel grants InMed exception to Dec 2, 2024 to show $1 bid price compliance for 10 consecutive trading days.
- Board approved 1-for-20 reverse stock split on Oct 29, 2024; shares would reduce from ~14.36M to ~718k.
- Reverse split requires no shareholder action; fractional shares not issued; trading symbol INM unchanged.
- Company must evidence compliance by Dec 2; no assurance of regaining compliance by that date.

## SEC filing metadata
- accession: 0001213900-24-094349
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390024094349/0001213900-24-094349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390024094349/ea0220029-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-094349
- JSON: https://secwatch.observer/filing/0001213900-24-094349.json
- Plain text: https://secwatch.observer/filing/0001213900-24-094349.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.